News

Beta Bionics, Inc. (Nasdaq: BBNX), a pioneering leader in the development of advanced diabetes management solutions, today ...
Second Quarter 2025 Financial Results and Highlights Revenue of $74.2 million, an increase of 10% year-over-yearCloud ARR of $85 million, an increase of 21% year-over-yearNon-GAAP diluted EPS of $0.28 ...
Beta Bionics, Inc. (Nasdaq: BBNX), a pioneering leader in the development of advanced diabetes management solutions, today reported its financial results ...